| Scintigraphy and therapy with radioiodine remains nuclear medicine’s cornerstone in the diagnosis and therapy of thyroid disease. In patients with recurrent or metastasized thyroid cancer that does not concentrate radioiodine, several other localizing techniques are available. Of these, 18FDG PET scanning has a high sensitivity and also a good image resolution. Combined CT-PET camera imaging is expected to gain importance in the clinical decision making in part of patients with thyroid cancer. Peptide receptor scintigraphy and radionuclide therapy with somatostatin analogues and in the near future also with other peptides e.g. CCK-B analogues may be of crucial importance in patients with DTC and MTC. If the uptake in the tumour sites is sufficiently high, diagnostic scanning may be followed by PRRT, whether with a sole radiopharmaceutical or a cocktail of radiolabelled peptides. |
